pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid has been researched along with Lung Neoplasms in 1 studies
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tatur, S | 1 |
| Groulx, N | 1 |
| Orlov, SN | 1 |
| Grygorczyk, R | 1 |
1 other study available for pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Lung Neoplasms
| Article | Year |
|---|---|
Ca2+-dependent ATP release from A549 cells involves synergistic autocrine stimulation by coreleased uridine nucleotides.
Topics: Adenosine Triphosphate; Apyrase; Autocrine Communication; Caffeine; Calcium; Calcium Signaling; Calc | 2007 |